hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06310122, orgStudyIdInfo id: ESWT on planter fascitis, briefTitle: Effect of Extracorporeal Shockwave Therapy on Gait Parameters in Patients With Planter Fascitis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2025-03-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: The purpose of this study is :* to determine the effect of extracorporeal shockwave on pain intensity in patients with plantar fasciitis.* to determine the effect of extracorporeal shockwave on foot function in patients with plantar fasciitis.* to determine the effect of extracorporeal shockwave on gait parameters in patients with plantar fasciitis, conditionsModule conditions: Plantar Fascitis, conditions: Extracorporeal Shockwave Therapy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Two groups : group (A), group (B) One of them will receive traditional treatment ( ultra sound, exercises) Other one will recieve extracorporeal shockwave therapy and traditional treatment also, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 52, type: ESTIMATED, armsInterventionsModule interventions name: Extracorporeal shockwave therapy, interventions name: ultrasound, outcomesModule primaryOutcomes measure: Stride length mean distance measured by (meter), primaryOutcomes measure: stride time mean time measured by (second), primaryOutcomes measure: speed mean distance/ time measured by (meter/second), primaryOutcomes measure: cadence mean number of steps /times., secondaryOutcomes measure: pain intensity level., otherOutcomes measure: Foot function, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310096, orgStudyIdInfo id: E-59394181-604.01-79277, briefTitle: Role of Thoracolumbar Fascia Stretching on Pain Parameters With Non-Specific Chronic Low Back Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-03-11, completionDateStruct date: 2024-03-11, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Atılım University, class: OTHER, collaborators name: Kirsehir Ahi Evran Universitesi, descriptionModule briefSummary: Role of Thoracolumbar Fascia Stretching on Pain Parameters with Non-Specific Chronic Low Back Pain, conditionsModule conditions: Pain, conditions: Low Back Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: TLF fascial stretching exercise, interventions name: conventional physiotherapy program., outcomesModule primaryOutcomes measure: Pain threshold, primaryOutcomes measure: Temporal summation, primaryOutcomes measure: NRS(Numerical rating scales), secondaryOutcomes measure: Pain Sensitivity Scale (PSS), secondaryOutcomes measure: Brief Pain Inventory (BPI), eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Atılım University, status: RECRUITING, city: Ankara, country: Turkey, contacts name: Naime Uluğ, PhD., role: CONTACT, phone: +905365434409, email: naime.ulug@atilim.edu.tr, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06310083, orgStudyIdInfo id: SMR for Turbinate Hypertrophy, briefTitle: Endoscopic Submucosal Resection Turbinoplasty VS Turbinectomy, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-01, primaryCompletionDateStruct date: 2024-01-31, completionDateStruct date: 2024-01-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Ahmed Nabil Selim, class: OTHER, descriptionModule briefSummary: The aim of our study is to compare endoscopic submucosal resection Turbinoplasty and partial inferior turbinectomy regarding clinical and radiological evaluation and its possible complications in the treatment of Chronic inferior turbinate hypertrophy., conditionsModule conditions: Turbinate; Hypertrophy Mucous Membrane, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A total of 40 patients were enrolled in the study. The patients were randomly classified into two groups, with 20 in each group.Group A (study group): who applied for Endoscopic submucosal resection Turbinoplasty.Group B (control group): Who applied for partial inferior turbinectomy., primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: The surgeons performed the nasal surgery and evaluating postoperative measurable outcomes was blinded about cases who were subjected to Endoscopic submucosal resection Turbinoplasty, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: Submucosal Resection Turbinoplasty Versus Partial Inferior Turbinectomy, outcomesModule primaryOutcomes measure: Nasal Obstruction, primaryOutcomes measure: Nasal Discharge, primaryOutcomes measure: Crustations, secondaryOutcomes measure: intra operative blood loss, secondaryOutcomes measure: Duration of operation (Minutes ), secondaryOutcomes measure: Hyposmia, otherOutcomes measure: Size Of Anterior part of Turbinate, otherOutcomes measure: Size Of Posterior part of Turbinate, otherOutcomes measure: Space of Anterior nasal Cavity, otherOutcomes measure: Space of posterior nasal Cavity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Al-Azhar University Hospital of Assiut, city: Assiut, zip: 17511, country: Egypt, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False
protocolSection identificationModule nctId: NCT06310070, orgStudyIdInfo id: IRB-23-1965, briefTitle: 3D Printed Personalized Ostomy Appliance, acronym: 3DPPOA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-03-05, primaryCompletionDateStruct date: 2025-03-05, completionDateStruct date: 2025-06-05, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Carilion Clinic, class: OTHER, collaborators name: Virginia Polytechnic Institute and State University, descriptionModule briefSummary: The goal of this clinical trial is to learn about the effectiveness of using a 3D scan for a personal ostomy appliance. The main question it aims to answer is:• Whether or not a 3D scan of a stoma reduces leakages and improves patient quality of life in regard to using a personalized ostomy appliance.Participants will* Spend 2 weeks with their standard of care ostomy appliance* Spend 2 weeks with their personalized ostomy appliance made from a 3D scan* Participate in daily surveys and weekly quality of life surveys conducted over the phone, conditionsModule conditions: 3D Printing, conditions: Ostomy, conditions: Leakage, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: 3D Printed Personalized Ostomy Appliance, outcomesModule primaryOutcomes measure: Incidence of Leaks, secondaryOutcomes measure: Number of appliances, secondaryOutcomes measure: Overall patient satisfaction, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310057, orgStudyIdInfo id: 4139, briefTitle: Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-03-01, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, class: OTHER, collaborators name: Incepta Pharmaceuticals Ltd, descriptionModule briefSummary: The goal of this clinical trial is to assess the efficacy of tofacitinib in refractory axial spodyloarthritis (ax-SpA) with dose escalation from 10mg to 15mg. Patients will start on 10mg and then divided into 2 groups (10 and 15) at 3rd month according to major improvement criteria.The main question\[s\] it aims to answer are:* Efficacy and safety of tofacitinib in different doses* If escalation of tofacitinib is justified if clinical criteria is not fulfilled at 10mg, conditionsModule conditions: Axial Spondyloarthritis, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Dose escalation study, all the patients will recieve 10mg tofacitinib at the beginning. Then at 3rd month, one group will continue at 10mg, if they fulfill the ASDAS major improvement criteria and other group will escalate to 15mg., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 92, type: ACTUAL, armsInterventionsModule interventions name: Tofacitinib, outcomesModule primaryOutcomes measure: To assess the ASDAS CRP major improvement criteria in refractory ax-SpA patients with dose escalation from 10mg to 15mg, secondaryOutcomes measure: Clinicodemographic characteristics of Ax-SpA, ASDAS CRP outcome rates, quality of life, adverse effects, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bangabandhu Sheikh Mujib Medical University, city: Dhaka, zip: 1000, country: Bangladesh, geoPoint lat: 23.7104, lon: 90.40744, hasResults: False
protocolSection identificationModule nctId: NCT06310044, orgStudyIdInfo id: Commiphora Myrrh, briefTitle: Effect of Commiphora Myrrh Solution as a Root Canal Irrigant on Post Operative Pain and Bacterial Load Reduction in Necrotic Tooth, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2025-01-01, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: Clinically compare the post-operative pain, incidences post-operative swelling, post-operative number of analgesic tablets taken by patient and amount of bacterial load reduction after using 50% Commiphora Myrrh Chemomechanical preparation, versus 2.5% NaOCl,in asymptomatic necrotic mandibular premolar treated in single visit., conditionsModule conditions: Necrotic Pulp, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: Root canal irrigant Commiphora Myrrh 50%, outcomesModule primaryOutcomes measure: Post-operative pain, secondaryOutcomes measure: incidence of Post-operative swelling, otherOutcomes measure: Amount of intracanal Bacterial CFUs/ml, otherOutcomes measure: Number of analgesic Counting Tablets taken by the patient after endodontic treatment, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310031, orgStudyIdInfo id: CL-00545, briefTitle: [Trial of device that is not approved or cleared by the U.S. FDA], statusModule overallStatus: WITHHELD, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: [Redacted], hasResults: False
protocolSection identificationModule nctId: NCT06310018, orgStudyIdInfo id: 2023A070902, briefTitle: Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE, acronym: SONIC-PE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-30, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Brigham and Women's Hospital, class: OTHER, collaborators name: Boston Scientific Corporation, descriptionModule briefSummary: SONIC-PE is a multicenter, prospective, single-arm study of 10 patients with bilateral PE treated with ultrasound-facilitated, catheter-directed lower-dose fibrinolysis (total dose 8 mg tPA given as 2 mg/hour/catheter over 2 hours) followed by 50 patients (total dose 6 mg tPA given as 3 mg/hour/catheter given over 1 hour) with the EKOS+™ system to determine its impact on the change in RV-to-LV diameter, refined Modified Miller Score, and distal pulmonary vascular blood volume as well as to assess International Society on Thrombosis and Haemostasis (ISTH) major bleeding., conditionsModule conditions: Pulmonary Embolism, conditions: Right Ventricular Dysfunction, conditions: Right Ventricular Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: multicenter, prospective, single-arm study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis, outcomesModule primaryOutcomes measure: Change in RV-to-LV diameter ratio as measured by chest CT from baseline to 48 ± 6 hours, primaryOutcomes measure: Frequency of ISTH major bleeding at 72 hours, secondaryOutcomes measure: Change in chest CT-measured blood volume in the distal pulmonary vasculature from baseline to 48 ± 6 hours, secondaryOutcomes measure: Change in refined Modified Miller Score as measured by chest CT from baseline to 48 ± 6 hours as measured by chest CT from baseline to 48 ± 6 hours, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310005, orgStudyIdInfo id: 1466-0003, briefTitle: A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-10-18, completionDateStruct date: 2024-10-18, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Boehringer Ingelheim, class: INDUSTRY, descriptionModule briefSummary: The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BI 3006337 in healthy male subjects following s.c. administration of single rising doses and multiple doses over 6 weeks., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Trial consists of a single-rising dose (SRD) and multiple dose (MD) part. In SRD part, the groups will be dosed consecutively in ascending order. The decision proceeding to MD part will be based upon safety and tolerability of all the preceding dose groups in SRD part. Within each dose group, patients will be randomized to either BI 3006337 or placebo., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: The trial is designed single-blind. The treatments administered (BI 3006337 or placebo) will be blinded to subjects but will be known to the investigators (outcome assessors)., whoMasked: PARTICIPANT, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: BI 3006337, interventions name: Placebo, outcomesModule primaryOutcomes measure: SRD + MD part: Percentage of patients with any treatment-emergent adverse event assessed as drug-related by the investigator, secondaryOutcomes measure: SRD part: Area under the concentration-time curve of BI 3006337 in serum over the time interval from 0 extrapolated to infinity (AUC0-inf), secondaryOutcomes measure: SRD part: Maximum measured concentration of BI 3006337 in serum (Cmax), secondaryOutcomes measure: MD part: Area under the concentration-time curve of BI 3006337 in serum over the dosing interval tau at steady state (AUCtau, ss) after the last dose in Week 6, secondaryOutcomes measure: MD part: Maximum measured concentration of BI 3006337 in serum at steady state (Cmax, ss) after the last dose in Week 6, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Clinical Research Hospital Tokyo, status: RECRUITING, city: Tokyo, Shinjuku-ku, zip: 160-0004, country: Japan, contacts name: Boehringer Ingelheim, role: CONTACT, phone: 0120201230, email: nippon@bitrialsupport.com, hasResults: False
protocolSection identificationModule nctId: NCT06309979, orgStudyIdInfo id: 111-903, briefTitle: A Study to Assess Growth in Children With Idiopathic Short Stature, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2040-12-31, completionDateStruct date: 2040-12-31, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: BioMarin Pharmaceutical, class: INDUSTRY, descriptionModule briefSummary: Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest., conditionsModule conditions: Idiopathic Short Stature, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 600, type: ESTIMATED, outcomesModule primaryOutcomes measure: Change in annualized growth velocity (AGV), primaryOutcomes measure: Change in Height Z-score, primaryOutcomes measure: Change in Standing Height, primaryOutcomes measure: Change in BMI, primaryOutcomes measure: Change in BMI Z-score, secondaryOutcomes measure: Frequency of event rates of medical events of interest, secondaryOutcomes measure: Frequency of Serious Medical Events, secondaryOutcomes measure: Association between specific variants and growth velocity, secondaryOutcomes measure: Association between other health outcomes directly related to short stature, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: Children's National Health System, status: RECRUITING, city: Washington, state: District of Columbia, zip: 20010, country: United States, geoPoint lat: 38.89511, lon: -77.03637, hasResults: False
protocolSection identificationModule nctId: NCT06309953, orgStudyIdInfo id: 937, briefTitle: A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2024-06-28, completionDateStruct date: 2024-06-28, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Bausch & Lomb Incorporated, class: INDUSTRY, descriptionModule briefSummary: An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease, conditionsModule conditions: Dry Eye, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Miebo, outcomesModule primaryOutcomes measure: Mean change from baseline (CFB) in dry eye symptom severity at Visit 3, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Site 205, status: NOT_YET_RECRUITING, city: Petaluma, state: California, zip: 94954, country: United States, geoPoint lat: 38.23242, lon: -122.63665, locations facility: Site 203, status: RECRUITING, city: Pittsburg, state: Kansas, zip: 66762, country: United States, geoPoint lat: 37.41088, lon: -94.70496, locations facility: Site 204, status: NOT_YET_RECRUITING, city: Stillwater, state: Minnesota, zip: 55082, country: United States, geoPoint lat: 45.05636, lon: -92.80604, locations facility: Site 202, status: RECRUITING, city: Kansas City, state: Missouri, zip: 64154, country: United States, geoPoint lat: 39.09973, lon: -94.57857, locations facility: Site 201, status: NOT_YET_RECRUITING, city: Brecksville, state: Ohio, zip: 44141, country: United States, geoPoint lat: 41.31978, lon: -81.62679, hasResults: False
protocolSection identificationModule nctId: NCT06309940, orgStudyIdInfo id: Basal ganglionic haemorrhage, briefTitle: Prognostic Factors for Surgical Management of Large Hypertensive Basal Ganglionic Haemorrhage, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: The aim of this study is to present current and comprehensive recommendations for surgical treatment of this hematoma and to determine the factors that may improve the survival rate, conditionsModule conditions: Basal Ganglionic Hemorrhage, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Prognostic factors of surgical evacuation of basal ganglionic haemorrhage, outcomesModule primaryOutcomes measure: Prognostic factors of surgical evacuation of basal ganglionic haemorrhage, eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 60 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False